Ikarian Capital, LLC Liquidia Corp Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.37 - $7.55 $821,956 - $1.84 Million	-243,904 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.14 - $7.38 $419,120 - $601,772	-81,541 Reduced 25.06%	243,904 $1.75 Million
Q4 2021 Feb 14, 2022	SELL	$2.71 - $5.17 $1.52 Million - $2.89 Million	-559,448 Reduced 63.22%	325,445 $1.58 Million
Q3 2021 Nov 15, 2021	SELL	$2.28 - $2.95 $12,635 - $16,348	-5,542 Reduced 0.62%	884,893 $2.44 Million
Q2 2021 Aug 16, 2021	SELL	$2.51 - $3.11 $153,022 - $189,601	-60,965 Reduced 6.41%	890,435 $2.55 Million
Q4 2020 Feb 12, 2021	BUY	$2.6 - $5.79 $2.47 Million - $5.51 Million	951,400 New	951,400 $2.81 Million

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.